News

In just under nine months, the Company has now raised over $220 million. Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics (RCT)

The injunction was obtained by Endo’s subsidiaries Par Pharmaceutical and Par Sterile Products (Par) from US District Judge Brian Martinotti. The order will prevent QuVa Pharma from marketing

BOTOX is the market-leading neuromodulator approved for the treatment of multiple indications and usage in the United States with additional approvals globally.  The addition of this product further

Under the terms of the agreement, GSK will use Covance Xcellerate® Monitoring, Xcellerate Insights, and Xcellerate Clinical Data Hub solutions in a software-as-a-service (SaaS) model. Covance technology products

ZTlido includes non-aqueous adhesive material containing 1.8% lidocaine, which will be applied to a non-woven polyester felt backing and covered with a polyethylene terephthalate (PET) film release liner.

The new independent biotech company, Viela Bio, will get six molecules from MedImmune's early-stage inflammation and autoimmunity programs. Viela Bio, which will get a funding of up to $250m, will

Ozanimod is being developed for the treatment of patients with relapsing forms of multiple sclerosis. Ozanimod is an oral and selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor

If approved, KP-470 will represent a novel drug with an alternate mechanism of action in the topical treatment of the disease. Under the terms of the licensing agreement,

The round was led by New Enterprise Associates, with participation from 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital,